Panamanian surgeons perform the first implant with SAPIEN 3 Ultra RESILIA technology. Through a minimally invasive procedure, the SAPIEN 3 Ultra RESILIA technology is positioned as a cutting-edge alternative for patients with aortic stenosis in the country. This event marks a precedent in the development of high-complexity medicine in the country. "The incorporation of this technology represents an important therapeutic alternative for younger patients with aortic stenosis who can benefit from a less invasive approach," stated Dr. Miguel Guerra. This launch positions the country at the forefront of cardiovascular surgery and structural cardiac intervention in the region, offering a technological alternative that, in selected cases, avoids the need for open-heart surgery.
Innovation in tissue and exceptional durability. The fundamental advance of this device lies in its innovative RESILIA tissue, a state-of-the-art technological processing developed by Edwards Lifesciences®. This component is designed to resist calcification — the hardening of tissues — much more effectively than conventional bioprostheses, resulting in superior durability of the implant. Aortic stenosis is a progressive condition that narrows the valve, making blood flow difficult and increasing the risk of heart failure. In addition to its use in severe cases of stenosis, the SAPIEN 3 Ultra RESILIA can be used in procedures called "valve-in-valve" to treat deteriorated previous bioprostheses.
Technical support and availability. The integration of these innovations is backed by specialized medical teams and the support of the Hospital Division of Droguería Ramón González Revilla, S.A., responsible for ensuring availability and the necessary technical accompaniment. Unlike traditional methods, transcatheter therapy allows the valve to be implanted using a catheter guided through the vascular system, reducing the invasiveness of the procedure for patients who meet the clinical criteria defined by a multidisciplinary team (Heart Team).
Medical milestone at Clínica Hospital San Fernando. Last Tuesday, March 17, Panamanian cardiovascular surgeons Dr. Miguel Guerra and Dr. Alfredo Matos, along with Dr. Adolfo Ferrero, an Argentine interventional cardiologist and proctor for the manufacturer, performed the first implant of this technology in Panama at Clínica Hospital San Fernando.
